Host Cell Targets for Unconventional Antivirals against RNA Viruses
Viruses · 2023
DOI: 10.3390/v15030776 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Vicky C Roa-Linares und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular and Translation Medicine Group, University of Antioquia, Medellin 050010, Colombia. Hauptthemen laut MEDLINE: Zika Virus Infection, Zika Virus, COVID-19, Viruses. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Tecnología e Innovación (Minciencias).
Abstract (Originalsprache)
The recent COVID-19 crisis has highlighted the importance of RNA-based viruses. The most prominent members of this group are SARS-CoV-2 (coronavirus), HIV (human immunodeficiency virus), EBOV (Ebola virus), DENV (dengue virus), HCV (hepatitis C virus), ZIKV (Zika virus), CHIKV (chikungunya virus), and influenza A virus. With the exception of retroviruses which produce reverse transcriptase, the majority of RNA viruses encode RNA-dependent RNA polymerases which do not include molecular proofreading tools, underlying the high mutation capacity of these viruses as they multiply in the host cells. Together with their ability to manipulate the immune system of the host in different ways, their high mutation frequency poses a challenge to develop effective and durable vaccination and/or treatments. Consequently, the use of antiviral targeting agents, while an important part of the therapeutic strategy against infection, may lead to the selection of drug-resistant variants. The crucial role of the host cell replicative and processing machinery is essential for the replicative cycle of the viruses and has driven attention to the potential use of drugs directed to the host machinery as therapeutic alternatives to treat viral infections. In this review, we discuss small molecules with antiviral effects that target cellular factors in different steps of the infectious cycle of many RNA viruses. We emphasize the repurposing of FDA-approved drugs with broad-spectrum antiviral activity. Finally, we postulate that the ferruginol analog (18-(phthalimide-2-yl) ferruginol) is a potential host-targeted antiviral.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular and Translation Medicine Group, University of Antioquia, Medellin 050010, Colombia.
- Molecular Mechanisms Program, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca, 37007 Salamanca, S…
ORCID-Profile: Vicky C Roa-Linares, Manuela Escudero-Flórez, Miguel Vicente-Manzanares, Juan C Gallego-Gómez
Förderung
- Ministerio de Ciencia, Tecnología e Innovación (Minciencias)
Zitieren
APA
Roa-Linares, V. C., Escudero-Flórez, M., Vicente-Manzanares, M., & Gallego-Gómez, J. C. (2023). Host Cell Targets for Unconventional Antivirals against RNA Viruses. Viruses. https://doi.org/10.3390/v15030776
Vancouver
Roa-Linares VC, Escudero-Flórez M, Vicente-Manzanares M, Gallego-Gómez JC. Host Cell Targets for Unconventional Antivirals against RNA Viruses. Viruses. 2023. doi:10.3390/v15030776
BibTeX
@article{RoaLinares2023,
author = {Roa-Linares, Vicky C and Escudero-Flórez, Manuela and Vicente-Manzanares, Miguel and Gallego-Gómez, Juan C},
title = {Host Cell Targets for Unconventional Antivirals against RNA Viruses},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15030776}
}
EUVIMED